FourThought Financial’s Nektar Therapeutics NKTR Stock Holding History

FourThought Financial’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-67	Closed	-$17K	–	1543
2021 Q3	$17K	Hold	67	–	–	﹤0.01%	987
2021 Q2	$17K	Hold	67	–	–	﹤0.01%	983
2021 Q1	$20K	Hold	67	–	–	﹤0.01%	905
2020 Q4	$17K	Buy	+67	New	+$17.3K	﹤0.01%	916

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

FourThought Financial's NKTR Position: Q4 2021 in Review

FourThought Financial sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 67 shares — an estimated $17K sold.

FourThought Financial first reported a position in NKTR in Q4 2020 and held it in 4 quarters. The position peaked at $20K in Q1 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

FourThought Financial reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
FourThought Financial sold 67 Nektar Therapeutics shares in Q4 2021, an estimated $17K.
FourThought Financial first reported a position in Nektar Therapeutics in Q4 2020 and held it in 4 quarters.
FourThought Financial's Nektar Therapeutics position peaked at $20K in Q1 2021.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on FourThought Financial's 13F filing for Q4 2021, filed 14 Jan 2022.